Samuel Broder (born in 1945) is an American oncologist and medical researcher.

He was a co-developer of some of the first effective drugs for the treatment of AIDS and was Director of the National Cancer Institute (NCI) from 1989 to 1995.

[1] In this position he oversaw the development of a number of new therapies for cancer including paclitaxel (Taxol).

After leaving the NCI, Dr. Broder became Senior Vice President for Research and Development at the IVAX Corporation in Florida, a position he held until 1998 when he joined Celera Genomics.

This biographical article related to medicine in the United States is a stub.